Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


IVD SECTOR QUARTERLIES ROUND-UP: Spending spree puts Inverness in red for Q4

This article was originally published in Clinica

Executive Summary

Charges resulting from a busy year of acquisition and integration activities have led to Inverness Medical Systems posting a net loss for the fourth quarter of 2007. The Waltham, Massachusetts-based diagnostics specialist recorded a deficit of $12.5m, a significant drop compared to the profit of $6m it made over the same period in 2006. Inverness' fourth-quarter net revenue rose by 83% to approximately $288m, largely helped by contributions from acquired businesses which boosted sales of the company's professional diagnostics products. This core business segment generated $234.2m in revenue ($139.3m derived from acquired product lines), a sharp rise compared to the same period in 2006, during which it made $87.2m.

You may also be interested in...

Pharmacogenetic Tests: US FDA Tries Off-Label Approach To Guide Consumers

US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.

Health And Wellness Trademark Review 18 February, 2020

Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.

Genfit Delays NASH Data While It Confers With US FDA On Methodology

Genfit will delay unblinding of data from its nearly complete Phase III study of elafibranor to get insight from the FDA on statistical methods in order to optimize its NDA.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts